Cargando…
Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
BACKGROUND: In Malaysia, for more than a decade, dipeptidyl peptidase-4 inhibitors (DPP-4i) are among the oral antidiabetic medications used as monotherapy or in combination to manage type II diabetes mellitus (T2DM). These medications are known for the efficacy in glycated haemoglobin (HbA1c) reduc...
Autores principales: | Mak, Woh Yon, Nagarajah, Jivanraj R., Abdul Halim, Hannah, Ramadas, Anitha, Mohd Pauzi, Zulsairi, Pee, Lay Ting, Jagan, Nirmala |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301996/ https://www.ncbi.nlm.nih.gov/pubmed/32566235 http://dx.doi.org/10.1186/s40545-020-00238-y |
Ejemplares similares
-
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022) -
Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022) -
Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022) -
Impact of COVID-19 pandemic on STEMI thrombolysis and Emergency Department's performance in a non-PCI capable tertiary hospital
por: Koh, Hock Peng, et al.
Publicado: (2022) -
Mortality outcomes and predictors of failed thrombolysis following STEMI thrombolysis in a non-PCI capable tertiary hospital: a 5-year analysis
por: Koh, Hock Peng, et al.
Publicado: (2023)